Pharmaceuticals

The pharmaceutical industry has been for decades one of the most profitable worldwide. Serious challenges, such as the expiry of long-term lucrative patents (Lipitor, to mention just one) and the cuts in healthcare and R&D in many countries worldwide, can pose a challenge to the growth of the industry. Which drug can save the life of the pharmaceutical industry? Highly differentiated strategies: this is what companies should focus on now if they want to stay competitive. Do you want to know more?

You can get a detailed picture of the market and refine your marketing, brand, and sales strategies with the reliable, up-to-date business information provided by the extensive range of reports, books and subscriptions listed under Research and Markets’ Pharmaceuticals category. They cover markets, companies (big Pharma, mid-sized specialty pharmaceutical companies, generic manufacturers, and small firms), technologies, e-healthcare, pharmaeconomics, drug discovery, and drug delivery.

The product coverage is huge. It includes OTC drugs as well disorder and goal-specific products related to respiration, oncology, vitamins, cardio, analgesics, central nervous system, generics, immune disorders, and women’s health. Show Less ... more

• Pipeline Insight: Lung Cancers Overview - Intensive R&D activity but little improvement in patient outcomes

  EURO€ 8,763.00USD$ 11,400.00GBP£ 7,372.00AUD$ 11,150.00JPY¥ 1,125,556.00SEK 74 851,00CHF 10'745.00CAD$ 11,616.00 Datamonitor, Dec 2010 , Pages: 167
  Introduction Despite advances in therapy, prognosis for non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) remains poor. The late-phase pipeline holds little promise for considerable...

• Pipeline Insight: Cancer Overview Malignant Melanoma, Neuroendocrine Tumors and Thyroid Cancer - New drug approvals likely after decades of little progress

  EURO€ 8,763.00USD$ 11,400.00GBP£ 7,372.00AUD$ 11,150.00JPY¥ 1,125,556.00SEK 74 851,00CHF 10'745.00CAD$ 11,616.00 Datamonitor, Dec 2010 , Pages: 268
  Introduction There are currently 100 drugs in the pipeline for melanoma, thyroid cancer and neuroendocrine tumors with 16 in late-stage. After years of little progress there are drugs in pre-registration...

• United Therapeutics Oral Treprostinil (UT-15C SR) - Likelihood of clinical trial and commercial success

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 LifeTech Research, Dec 2010 , Pages: 34
  UT-15C SR might be United Therapeutics’ fourth treprostinil formulation to reach the market, but as an oral agent it could be the most convenient of them all However, UT-15C SR’s road to market has...

• Forecast Insight: Depression - High rewards for novel and adjunctive therapies in treatment-resistant depression

  EURO€ 11,684.00USD$ 15,200.00GBP£ 9,830.00AUD$ 14,867.00JPY¥ 1,500,741.00SEK 99 801,00CHF 14'327.00CAD$ 15,488.00 Datamonitor, Dec 2010 , Pages: 124
  Introduction Generic erosion, particularly in the US, will contribute to an overall depression market decline from $11.9bn in 2009 to $11.2bn in 2019 across the seven major markets. In this cost-competitive...

• Fibromyalgia - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 38
  Fibromyalgia - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Fibromyalgia Pipeline Review, Q4 2010”, provides an overview of the Fibromyalgia therapeutic pipeline. This report provides...

• Idiopathic Pulmonary Fibrosis - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 63
  Idiopathic Pulmonary Fibrosis - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Idiopathic Pulmonary Fibrosis Pipeline Review, Q4 2010”, provides an overview of the Idiopathic Pulmonary...

• China Pharmaceutical Chain Industry Report, 2010

  EURO€ 922.00USD$ 1,200.00GBP£ 776.00AUD$ 1,174.00JPY¥ 118,480.00SEK 7 879,00CHF 1'131.00CAD$ 1,223.00 Research In China, Dec 2010 , Pages: 55
  Recent years have seen rapid growth of China’s pharmaceutical retail market, with expanding scale of chain enterprises and increasing number of drugstores, thanks to a fast-growing pharmaceutical industry...

• China Pharmaceutical Chain Industry Report, 2010

  EURO€ 922.00USD$ 1,200.00GBP£ 776.00AUD$ 1,174.00JPY¥ 118,480.00SEK 7 879,00CHF 1'131.00CAD$ 1,223.00 Research In China, Dec 2010 , Pages: 55
  Recent years have seen rapid growth of China’s pharmaceutical retail market, with expanding scale of chain enterprises and increasing number of drugstores, thanks to a fast-growing pharmaceutical industry...

• Stakeholder Insight: COPD in Emerging Markets (Brazil, India, China, US) - Key differences in treatment despite standardized guidelines

  EURO€ 11,684.00USD$ 15,200.00GBP£ 9,830.00AUD$ 14,867.00JPY¥ 1,500,741.00SEK 99 801,00CHF 14'327.00CAD$ 15,488.00 Datamonitor, Dec 2010 , Pages: 182
  Introduction While general COPD treatment patterns are consistent across the emerging markets compared to the US, some key distinctions between countries have been identified, which impact market potential...

• Macular Edema - Drug Pipeline Analysis and Market Forecasts to 2016

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 GlobalData, Dec 2010 , Pages: 39
  “Macular Edema Therapeutics - Pipeline Assessment and Market Forecasts to 2017” is an essential source of information and analysis on the global macular edema therapeutics market The report identifies...

• Cystic Fibrosis - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 81
  Cystic Fibrosis - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Cystic Fibrosis Pipeline Review, Q4 2010”, provides an overview of the Cystic Fibrosis therapeutic pipeline. This report...

• Dengue - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 41
  Dengue - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Dengue Pipeline Review, Q4 2010”, provides an overview of the Dengue therapeutic pipeline. This report provides information on the...

• Migraine - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 83
  Migraine - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Migraine Pipeline Review, Q4 2010”, provides an overview of the Migraine therapeutic pipeline. This report provides information...

• Colorectal Cancer - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 582
  Colorectal Cancer - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Colorectal Cancer Pipeline Review, Q4 2010”, provides an overview of the Colorectal Cancer therapeutic pipeline. This...

• Influenza - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 130
  Influenza - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Influenza Pipeline Review, Q4 2010”, provides an overview of the Influenza therapeutic pipeline. This report provides information...

• Anemia - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 129
  Anemia - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Anemia Pipeline Review, Q4 2010”, provides an overview of the Anemia therapeutic pipeline. This report provides information on the...

• Atrial Fibrillation - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 75
  Atrial Fibrillation - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Atrial Fibrillation Pipeline Review, Q4 2010”, provides an overview of the Atrial Fibrillation therapeutic pipeline....

• HIV-1 Infection - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 76
  HIV-1 Infection - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “HIV-1 Infection Pipeline Review, Q4 2010”, provides an overview of the HIV-1 Infection therapeutic pipeline. This report...

• Nonalcoholic Steatohepatitis (NASH) - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 44
  Nonalcoholic Steatohepatitis (NASH) - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Nonalcoholic Steatohepatitis (NASH) Pipeline Review, Q4 2010”, provides an overview of the Nonalcoholic...

• Non-Hodgkin Lymphoma - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 216
  Non-Hodgkin Lymphoma - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Non-Hodgkin Lymphoma Pipeline Review, Q4 2010”, provides an overview of the Non-Hodgkin Lymphoma therapeutic pipeline....

• Asthma - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 186
  Asthma - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Asthma Pipeline Review, Q4 2010”, provides an overview of the Asthma therapeutic pipeline. This report provides information on the...

• HIV / AIDS - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 383
  HIV / AIDS - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “HIV and Aids Pipeline Review, Q4 2010”, provides an overview of the HIV and Aids therapeutic pipeline. This report provides...

• Gastric Cancer - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 196
  Gastric Cancer - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Gastric Cancer Pipeline Review, Q4 2010”, provides an overview of the Gastric Cancer therapeutic pipeline. This report provides...

• Polycystic Ovarian Syndrome - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 37
  Polycystic Ovarian Syndrome - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Polycystic Ovarian Syndrome Pipeline Review, Q4 2010”, provides an overview of the Polycystic Ovarian Syndrome...

• Herpes Zoster - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 33
  Herpes Zoster - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Herpes Zoster Pipeline Review, Q4 2010”, provides an overview of the Herpes Zoster therapeutic pipeline. This report provides...

• Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 134
  Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Chronic Obstructive Pulmonary Disease (COPD) Pipeline Review, Q4 2010”, provides an overview...

• Type 1 Diabetes - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 103
  Type 1 Diabetes - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Type 1 Diabetes Pipeline Review, Q4 2010”, provides an overview of the Type 1 Diabetes therapeutic pipeline. This report...

• Hepatitis B - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 88
  Hepatitis B - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Hepatitis B Pipeline Review, Q4 2010”, provides an overview of the Hepatitis B therapeutic pipeline. This report provides...

• Urinary Incontinence - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 64
  Urinary Incontinence - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Urinary Incontinence Pipeline Review, Q4 2010”, provides an overview of the Urinary Incontinence therapeutic pipeline....

• Benign Prostatic Hyperplasia - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 63
  Benign Prostatic Hyperplasia - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Benign Prostatic Hyperplasia Pipeline Review, Q4 2010”, provides an overview of the Benign Prostatic Hyperplasia...

• Hemophilia - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 36
  Hemophilia - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Hemophilia Pipeline Review, Q4 2010”, provides an overview of the Hemophilia therapeutic pipeline. This report provides information...

• Premature Ejaculation - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 39
  Premature Ejaculation - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Premature Ejaculation Pipeline Review, Q4 2010”, provides an overview of the Premature Ejaculation therapeutic pipeline....

• Angina Pectoris - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 25
  Angina Pectoris - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Angina Pectoris Pipeline Review, Q4 2010”, provides an overview of the Angina Pectoris therapeutic pipeline. This report...

• Smoking Cessation - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 67
  Smoking Cessation - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Smoking Addiction Pipeline Review, Q4 2010”, provides an overview of the Smoking Addiction therapeutic pipeline. This...

• Type 2 Diabetes - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 227
  Type 2 Diabetes - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Type 2 Diabetes Pipeline Review, Q4 2010”, provides an overview of the Type 2 Diabetes therapeutic pipeline. This report...

• Dry Eye - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 67
  Dry Eye - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Dry Eye Pipeline Review, Q4 2010”, provides an overview of the Dry Eye therapeutic pipeline. This report provides information on...

• Hand Dermatitis - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 18
  Hand Dermatitis - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Hand Dermatitis Pipeline Review, Q4 2010”, provides an overview of the Hand Dermatitis therapeutic pipeline. This report...

• Major Depressive Disorder - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 95
  Major Depressive Disorder - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Major Depressive Disorder Pipeline Review, Q4 2010”, provides an overview of the Major Depressive Disorder therapeutic...

• Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 98
  Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Chronic Kidney Disease (Chronic Renal Failure) Pipeline Review, Q4 2010”, provides an overview...

• Acute Respiratory Distress Syndrome - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 29
  Acute Respiratory Distress Syndrome - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Acute Respiratory Distress Syndrome Pipeline Review, Q4 2010”, provides an overview of the Acute Respiratory...

• Otitis Media - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 32
  Otitis Media - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Otitis Media Pipeline Review, Q4 2010”, provides an overview of the Otitis Media therapeutic pipeline. This report provides...

• Candidiasis - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 33
  Candidiasis - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Candidiasis Pipeline Review, Q4 2010”, provides an overview of the Candidiasis therapeutic pipeline. This report provides information...

• Critical Limb Ischemia - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 44
  Critical Limb Ischemia - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Critical Limb Ischemia Pipeline Review, Q4 2010”, provides an overview of the Critical Limb Ischemia therapeutic...

• Postherpetic Neuralgia - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 44
  Postherpetic Neuralgia - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Postherpetic Neuralgia Pipeline Review, Q4 2010”, provides an overview of the Postherpetic Neuralgia therapeutic...

• Acne Vulgaris - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 50
  Acne Vulgaris - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Acne Vulgaris Pipeline Review, Q4 2010”, provides an overview of the Acne Vulgaris therapeutic pipeline. This report provides...

• Acne And Related Disorders - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 47
  Acne And Related Disorders - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Acne Pipeline Review, Q4 2010”, provides an overview of the Acne therapeutic pipeline. This report provides...

• Rheumatoid arthritis - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 185
  Rheumatoid arthritis - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Rheumatoid Arthritis Pipeline Review, Q4 2010”, provides an overview of the Rheumatoid Arthritis therapeutic pipeline....

• Prostate Cancer - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 321
  Prostate Cancer - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Prostate Cancer Pipeline Review, Q4 2010”, provides an overview of the Prostate Cancer therapeutic pipeline. This report...

• Head And Neck Cancer - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 235
  Head And Neck Cancer - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Head and Neck Cancer Pipeline Review, Q4 2010”, provides an overview of the Head and Neck Cancer therapeutic pipeline....

• Bronchitis - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 31
  Bronchitis - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Bronchitis Pipeline Review, Q4 2010”, provides an overview of the Bronchitis therapeutic pipeline. This report provides information...